EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Prognostic Significance, Radiological, and Metabolic Characteristics of Metastatic Lymph Nodes in Resectable Non‐Small Cell Lung Cancer Following Neoadjuvant Chemoimmunotherapy

Tianxiao Han iD, Sida Cheng iD, Xun Wang, QingYi Qi, Jinchuan Chen, Wenxiang Wang, Jian Zhou iD, Yun Li, Kezhong Chen, Hao Li iD, Fan Yang

Thoracic Cancer · 2025-05 · 16 (9)

DOI: 10.1111/1759-7714.70073 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thoracic Cancer, online erschienen am 14.05.2025. Verfasst von Tianxiao Han und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Thoracic Oncology Institute, Peking University People's Hospital, Beijing, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoadjuvant Therapy, Immunotherapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fundamental Research Funds for the Central Universities, Young Elite Scientists Sponsorship Program by CAST, Research Unit of Intelligence Diagnosis and Treatment in Early Non-small Cell Lung Cancer, Chinese Academy of Medical Sciences, Peking University Clinical Scientist Training Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Metastatic lymph nodes (mLNs) exhibit different responses to neoadjuvant immunotherapy compared to the primary tumor (PT) in non‐small cell lung cancer (NSCLC). Evaluating mLNs' response is crucial for predicting treatment efficacy and prognosis; however, such assessments are currently insufficient.

Methods

We enrolled 101 NSCLC patients with mLNs who underwent neoadjuvant chemoimmunotherapy followed by surgery. Survival outcomes and radiological and metabolic changes were analyzed across different lymph node pathological response groups, and a least absolute shrinkage and selection operator (LASSO) logistic regression model was developed to predict mLNs' response. RNA sequencing was performed to characterize the immune microenvironment of lymph nodes with different pathological responses.

Results

Residual tumors in mLNs were significantly associated with worse recurrence‐free survival ( p = 0.003) and a trend toward worse overall survival ( p = 0.087). Combining the pathological responses of mLNs and PTs improved prognostic stratification. Neither radiological size changes (AUC: 0.621) nor the SUVmax reduction rate (AUC: 0.645) were effective in distinguishing mLNs response. A model combining radiological and metabolic parameters demonstrated fair prediction efficacy (AUC: 0.85). In separate analyses of N1 and N2 nodes, radiological and metabolic changes of N1 mLNs partly reflected their pathologic response (AUC: 0.734; 0.816), unlike in N2 mLNs. RNA sequencing revealed that immune infiltration in responding lymph nodes differed from non‐responding ones, with higher CD8+ T cells, NK T cells, B cells, and dendritic cells in the former.

Conclusion

The pathological response of mLNs provides additional prognostic information, but current tools are ineffective for detecting residual tumors. A model integrating radiological and metabolic parameters may offer better prediction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsNeoadjuvant TherapyImmunotherapyLymph NodesHumansMaleFemalePrognosisMiddle AgedAgedLymphatic Metastasis

Stichwörter der Autor:innen

metastatic lymph nodesneoadjuvant chemoimmunotherapynon‐small cell lung cancerpathological responseprognosis

Autor:innen und Institutionen

  • Department of Thoracic Surgery, Thoracic Oncology Institute, Peking University People's Hospital, Beijing, China.
  • Department of Radiology, Peking University People's Hospital, Beijing, China.
  • Department of Nuclear Medicine, Peking University People's Hospital, Beijing, China.

ORCID-Profile: Tianxiao Han, Sida Cheng, Jian Zhou, Hao Li

Förderung

  • Fundamental Research Funds for the Central Universities, Young Elite Scientists Sponsorship Program by CAST
  • Research Unit of Intelligence Diagnosis and Treatment in Early Non-small Cell Lung Cancer, Chinese Academy of Medical Sciences
  • Peking University Clinical Scientist Training Program
  • Natural Science Foundation of Beijing Municipality
  • CAMS Innovation Fund for Medical Sciences
  • Peking University People's Hospital Scientific Research Development Funds
  • National Natural Science Foundation of China
  • Fundamental Research Funds for the Central Universities

Zitieren

APA

Han, T., Cheng, S., Wang, X., Qi, Q., Chen, J., Wang, W., Zhou, J., Li, Y., Chen, K., Li, H., & Yang, F. (2025). Prognostic Significance, Radiological, and Metabolic Characteristics of Metastatic Lymph Nodes in Resectable Non‐Small Cell Lung Cancer Following Neoadjuvant Chemoimmunotherapy. Thoracic Cancer, 16(9). https://doi.org/10.1111/1759-7714.70073

Vancouver

Han T, Cheng S, Wang X, Qi Q, Chen J, Wang W, et al. Prognostic Significance, Radiological, and Metabolic Characteristics of Metastatic Lymph Nodes in Resectable Non‐Small Cell Lung Cancer Following Neoadjuvant Chemoimmunotherapy. Thoracic Cancer. 2025;16(9). doi:10.1111/1759-7714.70073

BibTeX
@article{Han2025,
  author = {Han, Tianxiao and Cheng, Sida and Wang, Xun and Qi, QingYi and Chen, Jinchuan and Wang, Wenxiang and Zhou, Jian and Li, Yun and Chen, Kezhong and Li, Hao and Yang, Fan},
  title = {Prognostic Significance, Radiological, and Metabolic Characteristics of Metastatic Lymph Nodes in Resectable Non‐Small Cell Lung Cancer Following Neoadjuvant Chemoimmunotherapy},
  journal = {Thoracic Cancer},
  year = {2025},
  volume = {16},
  number = {9},
  doi = {10.1111/1759-7714.70073}
}
Kostenlos starten →